Absci Corporation (ABSI)

Market Cap	292.87M
Revenue (ttm)	4.53M
Net Income (ttm)	-103.11M
Shares Out	127.33M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	666,287
Open	2.285
Previous Close	2.480
Day's Range	2.275 - 2.359
52-Week Range	2.275 - 6.720
Beta	2.24
Analysts	Strong Buy
Price Target	7.60 (+230.44%)
Earnings Date	May 13, 2025

About ABSI

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 22, 2021
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: ABSI
• Website: https://www.absci.com

Financial Performance

In 2024, Absci's revenue was $4.53 million, a decrease of -20.71% compared to the previous year's $5.72 million. Losses were -$103.11 million, -6.75% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $7.6, which is an increase of 230.44% from the latest price.

Price Target

$7.6

(230.44% upside)

Analyst Consensus: Strong Buy